Marine Drugs (Apr 2021)

Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma

  • Gyu-Tae Park,
  • Jung-Won Yoon,
  • Sang-Bin Yoo,
  • Young-Chul Song,
  • Parkyong Song,
  • Hyoung-Kyu Kim,
  • Jin Han,
  • Sung-Jin Bae,
  • Ki-Tae Ha,
  • Natalia P. Mishchenko,
  • Sergey A. Fedoreyev,
  • Valentin A. Stonik,
  • Moon-Bum Kim,
  • Jae-Ho Kim

DOI
https://doi.org/10.3390/md19050237
Journal volume & issue
Vol. 19, no. 5
p. 237

Abstract

Read online

Scleroderma is an autoimmune disease caused by the abnormal regulation of extracellular matrix synthesis and is activated by non-regulated inflammatory cells and cytokines. Echinochrome A (EchA), a natural pigment isolated from sea urchins, has been demonstrated to have antioxidant activities and beneficial effects in various disease models. The present study demonstrates for the first time that EchA treatment alleviates bleomycin-induced scleroderma by normalizing dermal thickness and suppressing collagen deposition in vivo. EchA treatment reduces the number of activated myofibroblasts expressing α-SMA, vimentin, and phosphorylated Smad3 in bleomycin-induced scleroderma. In addition, it decreased the number of macrophages, including M1 and M2 types in the affected skin, suggesting the induction of an anti-inflammatory effect. Furthermore, EchA treatment markedly attenuated serum levels of inflammatory cytokines, such as tumor necrosis factor-α and interferon-γ, in a murine scleroderma model. Taken together, these results suggest that EchA is highly useful for the treatment of scleroderma, exerting anti-fibrosis and anti-inflammatory effects.

Keywords